Abstract
Major pharmaceutical advancements in the field of inflammatory bowel diseases benefit to children and adolescents affected with this progressive chronic condition. Scientific organisations such as ESPGHAN and ECCO actively publish guidelines related to the many aspects of care from these patients. Clinical studies and long-term prospective registries in the appropriate age groups are crucial to support an evidence based strategy.
Original language | English |
---|---|
Pages (from-to) | 461-464 |
Number of pages | 4 |
Journal | Immunopharmacology and Immunotoxicology |
Volume | 40 |
Issue number | 6 |
Early online date | 24 Jul 2018 |
DOIs | |
Publication status | Published - 24 Jul 2018 |
Keywords
- Inflammatory bowel disease
- children
- clinical studies
- pediatrics
- treatment